Clinical Trial Highlights

• Patients with mCRC Benefit from Active Maintenance Therapy
• Maintenance Therapy with ERL and BEV Prolongs Survival in Unresectable mCRC
• No Benefit to Adding BEV to Adjuvant CAP in CRC
• Neoadjuvant B and N Safe and Effective with D and H in HER2-Positive Breast Cancer
• Interim Safety Analysis of nP in High-Risk Early Breast Cancer
• Docetaxel Added to Anthracycline Regimens Benefits Patients with Highly Proliferative ER-Positive Breast Cancer
• Trial Will Evaluate Niraparib vs Placebo in Platinum-Sensitive Patients with Ovarian Cancer
• Everolimus Safe and Effective for Advanced pNET: Final Results of RADIANT-3
• Abiraterone Significantly Extends Survival in mCRPC
• ERA 223 to Study Radium-223 and Abiraterone in Combination in mCRPC
• Enzalutamide Plus Radiation Therapy for High-Risk Localized Prostate Cancer
• RAM Fails to Improve OS as Second-Line Treatment for Hepatocellular Cancer
• Phase 3 Trial to Compare Postoperative Chemotherapy with Observation in Stage I or II Endometrial Cancer
• SOR as Adjuvant Therapy after Resection for Pancreatic Cancer Does Not Improve DFS
• In Real-World Settings, EVE and EXE Extend PFS in Breast Cancer: BRAWO